Joshua Brody, Director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Straightforward snippet on bispecific, antibody, immunotherapy for lymphoma, the most transformational class of medicines for this disease since the battle began!
And a bit on the the ongoing efforts.”
You can also read:
Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview
